The $205 million PRV sale provides Fortress with substantial non-dilutive capital to fund its pipeline and operations. Monitor upcoming developments in its late-stage assets like dotinurad and the potential for additional milestone or royalty payments from its portfolio companies.
Price Chart
Executive Summary
Fortress Biotech reported full-year 2025 financial results, highlighted by a $205 million windfall from the sale of a Priority Review Voucher (PRV) following FDA approval of ZYCUBO. Despite a net loss of $1.9 million, the company generated $63.3 million in revenue, up from $57.7 million in 2024, driven by its dermatology portfolio and strategic asset monetizations.
Key Financial Metrics
Key Facts
- Subsidiary Cyprium Therapeutics sold a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million in gross proceeds.
- Fortress expects to receive at least $100 million from Cyprium via dividends and intercompany agreements following the PRV sale.
- Full-year 2025 consolidated net revenue was $63.3 million, up from $57.7 million in 2024, primarily from marketed dermatology products.
- Net loss attributable to common stockholders was $1.9 million in 2025, a significant improvement from a $55.9 million loss in 2024.
- Journey Medical, a partner company, reported net product revenues of $61.2 million for 2025, up from $55.1 million in 2024.
Financial Impact
$205 million from PRV sale, $63.3 million in annual revenue (up 9.7% YoY)
Risk Factors
- The $205 million PRV sale is a one-time event and not indicative of recurring revenue.
- Fortress remains reliant on the success of its subsidiaries and partner companies for future value creation.
- The company has a history of net losses and may continue to require external financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-037749 |
| Document: fbio-20260331x8k.htm | 0001104659-26-037749 |
| Document: 0001104659-26-037749-index-headers.html | 0001104659-26-037749 |
| Document: 0001104659-26-037749-index.html | 0001104659-26-037749 |
| Document: 0001104659-26-037749.txt | 0001104659-26-037749 |
| 8-K Data (Synthetic) | 0001104659-26-037749 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 14, 2026 23w ago | 8-K | $15.01 $19.62 | ▲ +30.68% | ▲ +26.16% | $16.14 (+7.53%) |
Mar 31, 2026 29w ago | 8-K | $13.55 $20.08 | ▲ +48.19% | ▲ +34.81% | $16.14 (+19.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers